ALK expects broad-based growth across sales regions and product groups in 2024 with tablet sales being key to growth. Profitability is expected to further improve, driven by revenue growth, benefits of scale and a reduction in external costs for clinical trials. Revenue is expected to grow by 9-12% in local currencies. The EBIT margin is expected at 17-19% against 14% in 2023. ALK’s CEO Peter Halling says: “We are pleased with the strategic and financial progress made in 2023, allowing us to deliver a solid set of results despite a challenging market environment. We now build on the momentum established in the second half of 2023, particularly in European tablet sales, and we expect that 2024 will mark the sixth consecutive year of revenue growth and improved earnings.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKBLF:
- ALK and McMaster researchers discover new cell that remembers allergies
- AKBLF Upcoming Earnings Report: What to Expect?
- ALK’s 2030 CO2 reduction targets have been approved by SBTi
- Release date of annual report 2023 for ALK and webcast
- ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review